Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy

Clinical Nephrology

Volumn 68, Issue 2, 2007, Pages 93-98

  Matsunaga, C ^a   Izumi, S ^a   Furukubo, T ^a   Satoh, M ^a   Yamakawa, T ^a   Uchida, T ^b   Kadowaki, D ^c   Hirata, S ^c  

^a Shirasagi Hospital   (Japan)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Calcium carbonate; Famotidine; Hemodialysis; Lansoprazole; Serum phosphate

Indexed keywords

CALCIUM; CALCIUM CARBONATE; FAMOTIDINE; LANSOPRAZOLE; PHOSPHATE; PHOSPHORUS; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; RECOMMENDED DRUG DOSE;

EID: 34547837522     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68093     Document Type: Article

References (16)

1. Burke SK. Arterial calcification in chronic kidney disease. Semin Nephrol. 2004; 24: 403-407.
2. Authority of the United States Pharmacopeial Convention. Drug information for the health care professional (USPDI) Vol 1. Willston: micromede; 2001.
3. Gladziwa U, Wagner S. Intragastric long-term pH metry in hemodialysis patients. A study with famotidine. Clin Nephrol. 1991; 36: 97-102.
4. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-1483.
5. Hardy P, Sechet A, Hottelart C, Oprisiu R, Abighanem O, Said S, Rasombololona M, Brazier M, Moriniere P, Achard J-M, Pruna A, Fournier A. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs. 1998; 22: 569-573.
6. Hirschowitz BI, Keeling D, Lewin M, Okabe S, Parsons M, Sewing K, Wallmark B, Sachs G. Pharmacological aspects of acid secretion. Dig Dis Sci. 1995; 2 (Suppl): 3S-23S.
7. Hongo M, Ohara S, Hirasawa Y, Abe S, Asaki S, Toyota T. Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing. Dig Dis Sci. 1992; 37: 882-890.
8. Kushihata S, Yorioka N. Effect of H2 blockers on serum calcium and phosphorus in hemodialysis patients on calcium carbonate therapy. Clin Nephrol. 1998; 50: 198-199.
9. Nolan CR. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int. 2005; 96: S7-S14.
10. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973; 4: 643-646.
11. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant. 1997; 12: 961-964.
12. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro and in vivo study. J Clin Invest. 1989; 83: 66-73.
13. Takahashi N, Shoji T, Matsubara K, Hitomi H, Hashimoto M, Kiyomoto H, Uchida K, Miki S, Hirohata M, Ishizu T, Akiyama K, Mizushige K, Matsuo H, Yuasa S. Effect of histamine H2 receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients. J Am Soc Nephrol. 1999; 10: 1090-1094.
14. Tan CC, Harden PN, Rodger RS, Rowe PA, Spooner RJ, Junor BJ, Briggs JD. Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant. 1996; 11: 851-853.
15. Var C, Gultekin F, Candan F, Turkay C, Sencan M, Icagasioglu S, Dokmetas S, Topcu S, Icli F, Var F, Egilmez R. The effects of hemodialysis on duodenal and gastric mucosal changes in uremic patients. Clin Nephrol. 1996; 45: 310-314.
16. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999; 9: 539-549.